Novartis AG EBIT

Novartis AG (NVS.TO) currently reports a EBIT of $17B as of June 2026. That compares with $17B in the prior-year period — up 2.3% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Novartis AG's EBIT history and peer comparisons.

Novartis AG's EBIT increased from $17B to $17B — a 2.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Novartis AG's EBIT of $17B is lower than the Healthcare sector average of $22B. That is roughly 22.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Novartis AG reported $17B in EBIT as of June 2026. That compares with $17B in the prior-year period — up 2.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $17B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Novartis AG, and consider following NVS.TO for alerts when major investors trade the stock.